Recombinant Human Hepassocin/FGL1 His-tag Protein, CF Summary
Leu23-Ile312, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol
|Shipping||The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human LAG-3 Fc Chimera (Catalog # 2319-L3) is coated at 1 μg/mL (100 μL/well), the concentration of Human Hepassocin/FGL1 His-tag (Catalog # 10285-HE) that produces 50% of the optimal binding response is 0.05-0.4 μg/mL.
2 μg/lane of Recombinant Human Hepassocin/FGL1 His-tag (Catalog # 10285-HE) was resolved withSDS-PAGE under reducing (R) and non reducing (NR) conditions and visualized by Coomassie® Blue staining, showing single bands at 33-37 kDa and 65-75 kDa, respectively.
Hepassocin, also known as hepatocyte-derived fibrinogen-related protein 1 (HFREP-1) and Fibrinogen-Like Protein 1 (FGL1) (1), is a liver-specific secreted protein belonging to the fibrinogen superfamily, whose members share a fibrinogen domain at their C-termini (2). Human Hepassocin/FGL1 is a secreted homodimer consisting of 312 amino acids (aa) with a 22 aa signal sequence and a 290 aa mature protein (3). Mouse and rat Hepassocin/FGL1 share approximately 84% and 83% amino acid identity with human Hepassocin/FGL1, respectively. Human Hepassocin/FGL1 binds LAG-3 through its fibrinogen-like domain independently of MHC class II (4). Hepassocin/FGL1 inhibits antigen-specific T cell activation, with its elevated presence in plasma of cancer patients indicating poor prognoses (4). Other than this role in cancer progression, Hepassocin/FGL1 also has restorative function for liver cells, as it is upregulated during liver regeneration following partial hepatectomy (5), and stimulates proliferation of hepatocytes in vivo and improves prognoses with fulminant hepatic failure in rats (6). Its expression is regulated in Hep G2 cells by interleukin-6 (IL-6) and is found in the serum in both bound and unbound states as an acute phase reactant (7).
- Yamamoto, T. et al. (1993) Biochem. Biophys. Res. Commun. 2:681.
- Zhang, S.M. et al. (2008) Innate Immun. 14:175.
- Hara, H. et al. (2001) Biochim. Biophys. Acta. 1520:45.
- Wang, J. et al. (2019) Cell. 176:334.
- Yu, HT. et al. (2009) J. Biol. Chem. 284:13335.
- Li, C.Y. et al. (2010) Gut. 59:817.
- Liu, Z. and C. Ukomadu. (2008) Biochem. Briophys. Res. Commun. 365:729.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human Hepassocin/FGL1 His-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Hepassocin/FGL1 His-tag Protein, CF and earn rewards!
Have you used Recombinant Human Hepassocin/FGL1 His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image